EHA2024 |The IMROZ study

Doctor Thierry Facon, professor of Haematology at Lille University Hospital in France explains the results of the Phase 3 IMROZ study, comparing isatuximab, bortezomib, lenalidomide and dexamethasone, known as Isa-VRd, versus VRd for transplant-ineligible patients with newly diagnosed myeloma at the European Hematology Association annual congress in Madrid, Spain.